Startup profile · funding coverage
HighLife funding, valuation and investors
Structural-heart medtech company that raised more than $90 million to advance a U.S. pivotal study and European commercialization.
Keep track of HighLife
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Growth financing
>$90M (€80M) · September 22, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Paris, France
Investors in latest funding
Lead: Andera Partners , Sofinnova Partners , Supernova Invest , Mérieux Equity Partners
Overview
HighLife develops transcatheter therapies for structural heart disease. On September 22, 2026 the company announced a financing of more than $90 million (€80 million), co-led by Andera Partners, Sofinnova Partners, Supernova Invest and Mérieux Equity Partners, with additional institutional and strategic investors.
Why HighLife is interesting
HighLife has a low-difficulty company query and a material clinical-stage financing that broadens VCT's healthcare coverage.
Key facts
- Sep 22, 2026: >$90M / €80M financing
- Capital supports a U.S. pivotal study and European commercialization
Funding history (newest first)
Growth financing
2026-09-22 >$90M (€80M)- Andera Partners (lead)
- Sofinnova Partners (lead)
- Supernova Invest (lead)
- Mérieux Equity Partners (lead)
Market / IPO context
Editorial / static context — not a live quote.
FAQs about HighLife
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.